Top 5 Low Price Companies To Buy Right Now

In the following video, Motley Fool consumer goods analyst Blake Bos discusses Netflix (NASDAQ: NFLX  ) , and whether investors should look at it as simply a new cable channel, or as something new that's going to change the television game entirely. He discusses why Netflix is able to offer such low prices for its streaming content, and what the business is dependent upon. He uses HBO as a comparison point to highlight what Netflix needs to do going into the future.

The tumultuous performance of Netflix shares since the summer of 2011 has caused headaches for many devoted shareholders. While the company's first-mover status is often viewed as a competitive advantage, the opportunities in streaming media have brought some new, deep-pocketed rivals looking for their piece of a growing pie. Can Netflix fend off this burgeoning competition, and will its international growth aspirations really pay off? These are must-know issues for investors, which is why The Motley Fool has released a premium report on Netflix. Inside, you'll learn about the key opportunities and risks facing the company, as well as reasons to buy or sell the stock. The report includes a full year of updates to cover critical new developments, so make sure to click here and claim a copy today.

Top Recreation Companies To Own For 2015: Omeros Corporation(OMER)

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company?s lead PharmacoSurgery product candidates include OMS103HP, a Phase 3 clinical program evaluated for OMS103HP?s safety and ability to improve postoperative joint function and reduce pain following arthroscopic partial meniscectomy surgery, and arthroscopic anterior cruciate ligament; OMS302, a Phase 2b clinical trial completed product candidate for use during ophthalmological procedures, including cataract and other lens replacement surgery; and OMS201, a Phase 1/Phase 2 clinical trial completed program for use durin g urological surgery. It also engages in developing proprietary compositions that comprise peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse. The company?s pipeline of preclinical product development programs includes Plasmin for Surgical and traumatic bleeding; PDE7 for addictions and compulsive disorders, and movement disorders; MASP-2 for macular degeneration, ischemia-reperfusion injury, transplant surgery, and radiation injury; and PDE10 for Schizophrenia. Omeros Corporation was founded in 1994 and is based in Seattle, Washington.

Advisors' Opinion:

• [By Monica Gerson]

  Omeros (NASDAQ: OMER) shares fell 2.80% to $8.32 in the pre-market trading. Omeros shares have dropped 9.80% over the past 52 weeks, while the S&P 500 index has gained 16.18% in the same period.

• [By John Udovich]

  Small cap orphan drug stocks Zalicus Inc (NASDAQ: ZLCS), Omeros Corporation (NASDAQ: OMER) and Viropharma Inc (NASDAQ: VPHM) have been active lately thanks to good news about their orphan drug treatments. In case you aren�� familiar with the term, orphan drug designation by the FDA is granted for drugs targeting conditions affecting 200,000 or fewer US patients annually that are expected to provide significant therapeutic advantage over existing treatments. The designation will also qualify companies for benefits across all stages of drug development, such as�accelerated approval processes, seven years of market exclusivity�after marketing approval, tax credits on�any US�clinical trials, grants and waiver of certain administrative fees.

• [By John Udovich]

  Last week had been a busy week for biotech IPOs and follow-on offerings plus news from small cap biotech stocks like Omeros Corporation (NASDAQ: OMER), Argos Therapeutics Inc (NASDAQ: ARGS), Revance Therapeutics Inc (NASDAQ: RVNC) and TNI BioTech (OTCMKTS: TNIB) that�� worth noting as a new trading week begins:�

Top 5 Low Price Companies To Buy Right Now: Airbus Group NV (EADSF)

Airbus Group NV, known as European Aeronautic Defence and Space Company EADS NV, is a Netherlands-based company active within the aerospace and defense sector. The Company manufactures aircrafts, helicopters, commercial space launch vehicles, missiles, satellites, defense systems and defense electronics, and offers services related to these activities. The Company oprates four divisions. The Airbus division comprises the Airbus Commercial and Airbus Military segments, which develop, manufacture, market and sell commercial jet aircrafts, military transport aircrafts and special mission aircrafts, among others. The Eurocopter division develops, markets and sells civil and military helicopters. The Astrium division develops, manufactures and sells satellites, orbital infrastructures and launchers, as well as provides space-related services. The Cassidian division develops, manufactures and sells missiles systems, military combat and training aircrafts, among others. Advisors' Opinion:

• [By Rich Smith]

  European plane maker and EADS (NASDAQOTH: EADSF  ) subsidiary Airbus announced Monday that one of its biggest, and most expensive planes, has just secured a big place in the airplane lineup at British Airways (BA).

• [By Alanna Petroff]

  Airbus, part of the pan-European aerospace conglomerate EADS (EADSF), is hoping that all airlines will adopt the 18-inch standard for long-haul flights.

Top 5 Low Price Companies To Buy Right Now: ProShares Short QQQ (PSQ)

ProShares Short QQQ is focused on daily investment results that correspond to the inverse (opposite) of the daily performance of the NASDAQ-100 Index. The NASDAQ-100 Index represents non-financial domestic and international issues listed on The NASDAQ Stock Market. The Fund takes positions in financial instruments (including derivatives) that in combination should have similar daily return characteristics as the inverse of the NASDAQ-100 Index. ProShares Short QQQ will not directly sell short the equity securities of issuers contained in the NASDAQ-100 Index. The Fund will concentrates its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. ProShare Advisors LLC serves as the investment advisor to the Fund. Advisors' Opinion:

• [By MONEYMORNING.COM]

  It's the ProShares Short QQQ (NYSE: PSQ). The good thing about this type of inverse ETF is that it pays you when the Nasdaq drops roughly on a 1-to-1 basis. For every percentage point the index goes down, PSQ rises by that amount.

Top 5 Low Price Companies To Buy Right Now: iShares MSCI Emerging Markets ETF (EEM)

iShares MSCI Emerging Markets Index Fund (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the MSCI Emerging Markets Index (the Index). The Index is designed to measure equity market performance in the global emerging markets. The Index was developed by Morgan Stanley Capital International Inc. as an equity benchmark for emerging market stock performance. The Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion in the Index. The Index is reviewed quarterly.

The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund's investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:

• [By Holly LaFon]

  Dalio�� portfolio contains 261 stocks, and 32 percent of it is now in emerging markets ETFs. His biggest purchases during the fourth quarter were Vanguard Emerging Markets ETF (VWO), iMCSI Emerging Markets Index Fund (EEM), BMC Software (BMC), Watson Pharmaceuticals (WPI) and Berkshire Hathaway Inc. B Shares (BRK.B).